GlassScriptPhysician profile
Emily Bertsch
NPI 1356869267
$1,517.51
in general payments reported to CMS, 2019-2025
30 companies · $819 in 2025
The $819 reported for 2025 was more than what 81% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $137 · 2024: $562 · 2025: $819.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,518.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,517.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $233.40 | 2023-2025 | |
| Incyte Corporation | $139.10 | 2024-2025 | Monjuvi, Zynyz, Pemazyre |
| Genentech USA, INC. | $115.67 | 2024-2025 | Polivy, Venclexta, Tecentriq |
| Merck Sharp & Dohme LLC | $114.39 | 2024-2025 | Keytruda, Lynparza, Welireg |
| Takeda Pharmaceuticals U.S.A., INC. | $73.77 | 2024-2025 | Ninlaro, Alunbrig, Fruzaqla |
| Genzyme Corporation | $71.41 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $70.46 | 2025 | |
| Janssen Biotech, INC. | $68.46 | 2024-2025 | Darzalex, Talvey, Tecvayli |
| Daiichi Sankyo INC. | $55.56 | 2025 | Datroway, Enhertu |
| Eisai INC. | $53.27 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $50.40 | 2023-2025 | Opdivo |
| Pfizer INC. | $45.59 | 2024-2025 | |
| Aveo Pharmaceuticals, INC. | $39.38 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $37.48 | 2025 | Calquence, Enhertu |
| Adc Therapeutics America, INC. | $33.47 | 2023-2024 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $32.62 | 2025 | Reblozyl |
| Array Biopharma INC | $30.60 | 2025 | Braftovi, Tukysa, Mektovi |
| Genmab U.S., INC. | $29.31 | 2024-2025 | Epkinly |
| Stemline Therapeutics INC. | $23.05 | 2025 | Orserdu |
| Ipsen Biopharmaceuticals, INC | $22.30 | 2024 | Somatuline Depot, Onivyde |
| Bayer Healthcare Pharmaceuticals INC. | $20.82 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $19.77 | 2025 | Libtayo |
| Boston Scientific Corporation | $19.43 | 2023 | Watchman Flx |
| Pharmacosmos Therapeutics INC. | $19.02 | 2024 | Cosela |
| Beigene USA, INC. | $18.53 | 2024 | Brukinsa |
| Abbvie INC. | $18.10 | 2024 | |
| Glaxosmithkline, LLC. | $17.44 | 2024 | Jemperli, Zejula |
| Syndax Pharmaceuticals, INC. | $15.01 | 2025 | |
| Beone Medicines USA, INC. | $14.99 | 2025 | Brukinsa |
| Emd Serono, INC. | $14.71 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Bertsch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.